{"id":"NCT03066609","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis","officialTitle":"A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab, to Demonstrate Efficacy After Twelve Weeks of Treatment and to Assess Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis With or Without Psoriatic Arthritis Comorbidity","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-02-28","primaryCompletion":"2017-12-21","completion":"2018-11-20","firstPosted":"2017-02-28","resultsPosted":"2019-12-30","lastUpdate":"2019-12-30"},"enrollment":543,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"Secukinumab 150 mg s.c.","otherNames":[]},{"type":"DRUG","name":"Secukinumab 300 mg s.c.","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Secukinumab 150mg","type":"EXPERIMENTAL"},{"label":"Secukinumab 300mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to determine if secukinumab is effective and safe in the treatment of plaque type psoriasis","primaryOutcome":{"measure":"Psoriasis Area and Severity Index (PASI) 75 (Multiple Imputation)","timeFrame":"Week 12","effectByArm":[{"arm":"Secukinumab 150mg","deltaMin":112,"sd":null},{"arm":"Secukinumab 300mg","deltaMin":254,"sd":null},{"arm":"Placebo","deltaMin":6,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":32,"countries":["China","Hungary","Malaysia","Philippines","Thailand","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["33060370"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":136},"commonTop":["Upper respiratory tract infection","Hyperuricaemia","Nasopharyngitis","Diarrhoea","Influenza"]}}